A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Hope for Alzheimer's prevention emerges as scientists find existing seizure drug may stop disease progression if taken ...

Researchers identify prochlorperazine as a potential new treatment for temporal lobe epilepsy by restoring the KCC2 chloride ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...

According to a real-world study, cenobamate was effective in patients with drug-resistant epilepsy (DRE), with 49.3% of patients achieved a 50% or greater reduction in seizure frequency at 3 months.

A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, ...

Assistant Professor of Neurology, The Johns Hopkins University School of Medicine. Baltimore, Md. Alcohol-induced seizures are withdrawal phenomena and do not respond to chronic anticonvulsants. [7] ...

Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.